The main driving factor was the announcement that AST SpaceMobile had been selected as a prime contractor for the U.S. Missile Defense Agency’s SHIELD program.
In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to Keytruda alone, following three years...